

I hereby certify that this correspondence is being filed via
EFS-Web with the United States Patent and Trademark Office
on July 9, 2007

PATENT
Attorney Docket No.: 082368-009500US
Client Reference No.: ONC-A0413P-US

TOWNSEND and TOWNSEND and CREW LLP

By: /Brien M. Bergner/
Brien M. Bergner

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Yusuke NAKAMURA et al.

Application No.: 10/590,801

Int'l. Filing Date: February 18, 2005

For: EPHA4 AS THERAPEUTIC
TARGET OF PRC AND PDACA

Confirmation No.: 8376

Examiner: Not Yet Assigned

Art Unit: Not Yet Assigned

INFORMATION DISCLOSURE
STATEMENT UNDER 37 CFR §1.97 and
§1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. In compliance with the requirements of 37 CFR §1.98(a)(2), copies of U.S. references 0001-0004 are not enclosed; copies of references 0005-0020 and 0022 are enclosed.

Reference 0010 corresponds to Reference 0009, the publication of the international application for which the EPO is a designated office. As such, Reference 0010 was not republished by the EPO according to article 158(1) EPC. A copy of the EP publication face page for Reference 0010 is enclosed.

Reference 0021 is not enclosed. A copy of this reference is not provided as it was cited in the International Search Report, and as such, should have been provided directly by the

WIPO under the exchange program between the USPTO, the EPO, and the JPO. A copy of the Search Report is enclosed.

It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR §1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that no fee is required for submission of this statement. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

/Kevin Bastian/

Kevin Bastian
Reg. No. 34,774

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: 415-576-0200
Fax: 415-576-0300
KLB:bmb
61086971 v1

Substitute for form 1449A&B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	
				10/590,801	
				Filing Date	
				February 18, 2005	
				First Named Inventor	
		Nakamura, Yusuke			
Art Unit					
Examiner Name				Not Yet Assigned	
Sheet	1	of	2	Attorney Docket Number	082368-009500US

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	0001	US-6,071,697 A	06-06-2000	SOSA-PINEDA, Beatriz and Peter Gruss	
	0002	US-6,335,170 B1	01-01-2002	ORNTOFF, Torben F.	
	0003	US-6,506,607 B1	01-14-2003	SHYJAN, Andrew W.	
	0004	US-2005-0260639 A1	11-24-2005	NAKAMURA, Yusuke, et al.	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures	T ²
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
	0005	WO	95/026484	A1	10-26-1995	Amgen, Inc.		<input type="checkbox"/>
	0006	WO	01/57270	A2	08-09-2001	Molecular Dynamics, Inc.		<input type="checkbox"/>
	0007	WO	02/030268	A2	04-18-2002	EOS Biotechnology, Inc.		<input type="checkbox"/>
	0008	WO	03/009814	A2	02-06-2003	Millennium Pharmaceuticals, Inc.		<input type="checkbox"/>
	0009	WO	2004/031412	A2	04-15-2004	Oncotherapy Science, Inc. and The University of Tokyo		<input type="checkbox"/>
	0010	EP	1 549 771	A2	07-06-2005	Oncotherapy Science, Inc. and The University of Tokyo		<input type="checkbox"/>

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	0011	ASHIDA, Shingo, et al.; "Molecular Features of the Transition from Prostatic Intraepithelial Neoplasia (PIN) to Prostate Cancer: Genome-wide Gene-expression Profiles of Prostate Cancers and PINs;" <u>Cancer Research</u> ; September 1, 2004; pp. 5963-5972; 64:17.			<input type="checkbox"/>
	0012	CARLES-KINCH, Kelly, et al.; "Antibody Targeting of the EphA2 Tyrosine Kinase Inhibits Malignant Cell Behavior;" <u>Cancer Research</u> ; May 15, 2002; pp. 2840-2847; 62:10.			<input type="checkbox"/>
	0013	COFFMAN, Karen T., et al.; "Differential EphA2 Epitope Display on Normal versus Malignant Cells;" <u>Cancer Research</u> ; November 15, 2003; pp. 7907-7912; 63:22.			<input type="checkbox"/>
	0014	DODELET, Vincent C. and Elena B. Pasquale; "Eph receptors and ephrin ligands: embryogenesis to tumorigenesis;" <u>Oncogene</u> ; November 20, 2000; pp. 5614-5619; 19:49.			<input type="checkbox"/>
Examiner Signature					Date Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		<i>Application Number</i>	10/590,801
		<i>Filing Date</i>	February 18, 2005
		<i>First Named Inventor</i>	Nakamura, Yusuke
		<i>Art Unit</i>	
		<i>Examiner Name</i>	Not Yet Assigned
<i>(Use as many sheets as necessary)</i>		<i>Attorney Docket Number</i>	082368-009500US
Sheet	2	of	2

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	0015	DOTTORI, Mirella, et al.; "EphA4 (Sek1) receptor tyrosine kinase is required for the development of the corticospinal tract;" <u>Proceedings of the National Academy of Sciences of the United States of America (PNAS)</u> ; October 27, 1998; pp. 13248-13253; 95:22.	<input type="checkbox"/>
	0016	GALE, Nicholas W. and George D. Yancopoulos; "Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, Angiopoietins, and ephrins in vascular development;" <u>Genes & Development</u> ; May 1, 1999; pp. 1055-1066; 13:9.	<input type="checkbox"/>
	0017	IRVING, Carol, et al.; "Progressive Spatial Restriction of <i>Sek-1</i> and <i>Krox-20</i> Gene Expression during Hindbrain Segmentation;" <u>Developmental Biology</u> ; January 10, 1996; pp. 26-38; 173:1.	<input type="checkbox"/>
	0018	KULLANDER, Klas, et al.; "Kinase-Dependent and Kinase-Independent Functions of EphA4 Receptors in Major Axon Tract Formation In Vivo;" <u>Neuron</u> ; January 2001; pp. 73-84; 29:1.	<input type="checkbox"/>
	0019	KULLANDER, Klas and Rüdiger Klein; "Mechanisms and Functions of Eph and Ephrin Signalling;" <u>Nature Review: Molecular Cell Biology</u> ; July 2002; pp. 475-486; 3:7.	<input type="checkbox"/>
	0020	MURAI, Keith K. and Elena B. Pasquale; "Eph'ective signaling: forward, reverse and crosstalk;" <u>Journal of Cell Science</u> ; July 15, 2003; pp. 2823-2832; 116: Pt. 14.	<input type="checkbox"/>
	0021	NAKAMURA, T., et al.; "Genome-wide cDNA microarray analysis of gene expression profiles in pancreatic cancers using populations of tumor cells and normal ductal epithelial cells selected for purity by laser microdissection;" <u>Oncogene</u> ; March 25, 2004; pp. 2385-2400; 23:13.	<input type="checkbox"/>
	0022	YAO, Virginia J., et al.; "Targeting Pancreatic Islets with Phage Display Assisted by Laser Pressure Catapult Microdissection;" <u>American Journal of Pathology</u> ; February 2005; pp. 625-636; 166:2.	<input type="checkbox"/>

Examiner Signature	Date Considered
-----------------------	--------------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.